Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M309486200 on October 7, 2003

J. Biol. Chem., Vol. 278, Issue 51, 51261-51266, December 19, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/51/51261    most recent
M309486200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woelfle, J.
Right arrow Articles by Rotwein, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woelfle, J.
Right arrow Articles by Rotwein, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Mechanisms of Growth Hormone (GH) Action

IDENTIFICATION OF CONSERVED Stat5 BINDING SITES THAT MEDIATE GH-INDUCED INSULIN-LIKE GROWTH FACTOR-I GENE ACTIVATION*

Joachim Woelfle{ddagger}§, Dennis J. Chia{ddagger}||, and Peter Rotwein{ddagger}**

From the {ddagger}Molecular Medicine Division, Department of Medicine and Division of Endocrinology, Department of Pediatrics, Oregon Health & Science University, Portland, Oregon 97239-3098

Received for publication, August 26, 2003 , and in revised form, October 6, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Many of the actions of growth hormone (GH) on somatic growth and tissue maintenance are mediated by insulin-like growth factor-I (IGF-I), a secreted protein whose gene expression is rapidly and potently induced by GH by unknown mechanisms. Recent studies implicating Stat5a and Stat5b in the growth response to GH in mice and observations linking Stat5b to control of IGF-I gene transcription in rats have prompted the current investigations into the molecular determinants of a putative regulatory network extending from GH through Stat5b to IGF-I. Here we characterize as critical components of this hormone-activated transcriptional pathway two adjacent Stat5 binding sites in the second intron of the rat IGF-I gene located within a conserved region previously found to undergo acute and reversible changes in chromatin structure after in vivo GH treatment. As assessed by chromatin immunoprecipitation assays, GH rapidly induced binding of Stat5 to this DNA segment in the liver of GH-deficient rats, just prior to the onset of transcription from both major and minor IGF-I gene promoters. Biochemical reconstitution experiments showed that the two intronic Stat5 DNA elements were able to bind Stat5b in vitro after GH treatment could transmit GH- and Stat5b-dependent transcriptional responsiveness to the major IGF-I promoter and to a minimal neutral gene promoter and were required for full stimulation of reporter gene activity by GH. Taken together, these results identify an intronic enhancer as a key mediator of GH-induced IGF-I gene transcription working through Stat5b and provide new insight into the molecular architecture of this transcriptional pathway.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The biological effects of growth hormone (GH)1 on somatic growth and tissue regeneration have been inextricably linked with the actions of insulin-like growth factor-I (IGF-I) ever since the somatomedin hypothesis was first formulated over 47 years ago (1). Much is now known regarding the molecular physiology and biochemistry of both proteins (2, 3), and although several of the actions of GH do not require IGF-I (4) and IGF-I is not exclusively regulated by GH (3, 5, 6), their interdependent roles in controlling normal growth during childhood and maintaining tissue integrity during aging have been both confirmed and amplified in the intervening years (7-10).

GH initiates its physiological effects after binding to the transmembrane GH receptor and activating JAK2, a receptor-associated intracellular tyrosine protein kinase (2), thereby setting into motion a series of protein phosphorylation cascades that lead to the activation of several transcription factors including AP-1 and Stats1, 3, 5a, and 5b among others (11). It has been known for over a decade that GH rapidly and potently induces IGF-I gene transcription in vivo (12), leading to the sustained production of IGF-I mRNAs and protein (12, 13), yet the signaling pathways connecting the GH receptor and cytoplasmic Jak2 to the nuclear IGF-I gene have remained uncharacterized. Contributing to this challenge is the fact that the IGF-I gene is more complicated that its simple protein structure would have predicted. In mammals, the gene is transcribed from two promoters, each with unique leader exons, and its initial transcripts undergo both alternative splicing and differential polyadenylation to yield multiple mature mRNA species (14).

Recent studies from our laboratory have implicated the transcription factor Stat5b as a key component in acute GH-stimulated IGF-I gene activation in rats (15), thereby extending previous observations pointing to roles for Stat5b and to a lesser extent Stat5a in controlling normal somatic growth in mice (16, 17) but not elucidating molecular mechanisms. Here we use a combination of in vivo observations in GH-deficient rats and biochemical reconstitution experiments in tissue culture cells to identify a region within the IGF-I gene that binds Stat5 in a GH-dependent manner and is capable of mediating GH-stimulated IGF-I gene activation via this transcription factor.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Antibodies to Stat5 (C17X) were from Santa Cruz Biotechnology (Santa Cruz, CA), and antibodies to anti-FLAG (M2) were from Sigma. Recombinant rat GH was from the National Hormone and Pituitary Program, NIDDK, National Institutes of Health. Oligonucleotides were synthesized at the Oregon Health & Sciences University Core Facility. Transit-LT1 was purchased from Mirus (Madision, WI), protein A-agarose beads were from Sigma, and the Qiaquick PCR DNA purification kit was from Qiagen (Valencia, CA). All of the other chemicals were reagent grade and were obtained from commercial suppliers.

Recombinant Plasmids—A plasmid in pGL2 has been described encoding 1711 bp of rat IGF-I promoter 1 and the first 328 bp of exon 1 (18). An 825-bp fragment of rat IGF-I intron 2 was added 5' to the promoter by standard molecular cloning methods. The mouse GH receptor in pcDNA3 was a gift from Dr. F. Talamantes (University of California, Santa Cruz, CA), and rat Stat5b in pcDNA3 was from Dr. Christin Carter-Su (University of Michigan, Ann Arbor, MI). The latter was modified by site-directed mutagenesis to add an NH2-terminal FLAG epitope tag, and point mutations were introduced to create constitutively active Stat5b (Stat5bCA, N699H) as described previously (15). Thymidine kinase luciferase was from Dr. Susan Berry (University of Minnesota, Minneapolis, MN). It was modified by the addition of portions of rat IGF-I intron 2 as indicated in Fig. 5.



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 5.
GHRE-1 and GHRE-2 mediate GH-stimulated and Stat5b-regulated gene transcription. Results of luciferase assays in COS-7 cells transiently transfected with expression plasmids encoding the mouse GH receptor and wild-type rat Stab5b and incubated with rat GH (40 nM) or vehicle for 18 h. A, luciferase reporter genes were included that contained the minimal thymidine kinase (TK) promoter alone or with either 932 or 84 bp of DNA from the HS7 region of the rat IGF-I gene (thin lines). GHRE-1 and GHRE-2 are indicated by shaded circles. B, luciferase reporter genes were used that contained the minimal TK promoter alone or with 84 bp of DNA from HS7 encoding either wild type or mutant versions of GHRE-1 and GHRE-2. Mutant sequences are indicated by an X (for GHRE-1, TTCCTGGAA was changed to GTCCTGGTA, and for GHRE-2, TTCTTAGAA was changed to GTCTTAGTA). For both A and B, the graphs summarize the results of 3-5 independent experiments, each performed in duplicate (*, p < 0.01; **, p < 0.02 versus no GH or no Stat5b). Luciferase values for the TK promoter ranged from 4,000 to 8,000 relative light units/10 s.

 
Transient Transfections and Reporter Gene Assays—COS-7 cells (from ATCC) were incubated in media under conditions described previously (15) and were co-transfected with expression plasmids for the mouse GH receptor and wild type Stat5b or Stat5bCA using Transit-LT1 and a protocol from the supplier. After incubation for 24 h, serum-free medium was added containing 1% bovine serum albumin for 8 h followed by the addition of recombinant rat GH (40 nM final concentration) or vehicle for 30 min. Cells were then harvested, and nuclear proteins were isolated (19). For reporter gene assays, cells on 6-well tissue culture dishes were co-transfected with mouse GH receptor (750 ng) and wild type Stat5b (750 ng) and the promoter-reporter plasmids indicated in Figs. 4 and 5 (750 ng). Cells were incubated for 24 h followed by the addition of serum-free medium containing 1% bovine serum albumin and either rat GH or vehicle for 18 h. Cells were then harvested, and cell lysates were used for luciferase assays. All of the results were normalized for total cellular protein values.



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 4.
The HS7 region mediates GH-stimulated and Stat5b-regulated transcription of the major rat IGF-I promoter. Results of luciferase assays in COS-7 cells transiently transfected with expression plasmids encoding the mouse GH receptor and wild-type rat Stab5b and incubated with rat GH (40 nM) or vehicle for 18 h. Each luciferase reporter gene contained 1711 base pairs of rat IGF-I promoter 1 and 328 base pairs of rat IGF-I exon 1 (IGF-I P1). An 825-bp segment from the HS7 region was cloned 5' to P1 and included GHRE-1 and GHRE-2 (IGF-I P1 + HS7). The graph summarizes results of four independent experiments (mean ± S.E.), each performed in duplicate (*, p < 0.02 versus other conditions). Luciferase values for IGF-I P1 ranged from 8,000 to 12,000 relative light units/10 s.

 
Animal Studies—Male Sprague-Dawley rats, hypophysectomized by a transauricular route at age 7 weeks, were purchased from Harlan Sprague-Dawley (Indianapolis, IN). Animals were housed at the OHSU Animal Care Facility on a 12-h light/dark schedule with free access to food and water and received care according to National Institutes of Health guidelines. All of the procedures were approved by the OHSU Animal Care and Use Committee. Glucocorticoids (cortisol phosphate, 400 µg/kg/day) and thyroxine (10 µg/kg/day) were replaced by daily subcutaneous injection, and GH deficiency was confirmed by failure to grow during a 2-week observation period. Following this interval, rats were injected intraperitoneally with either vehicle (saline) or 1.5 µg/g recombinant rat GH. At intervals, rats were anesthetized with pentobarbital (50 mg/kg intraperitoneally) and sacrificed. Liver proteins were isolated as described previously (19) as well as RNA and DNA outlined below.

DNA-Protein Binding Studies—Electrophoretic mobility shift assays were performed as described previously (15, 19) with 10 µg of COS-7 or rat hepatic nuclear proteins and 5'-fluorescein-labeled double-stranded oligonucleotides from rat GHRE-1 (top strand, 5'-GGGCCTTCCTGGAAGAAA-3'), GHRE-2 (top strand, 5'-TCTGTCTGCTTCTTAGAATGAAGAGAGA-3'), or with a binding site for Sp1 (top strand, 5'-ATTCGATCGGGGCGGGGCGAGC-3'). After incubation of proteins and DNA for 30 min at 4 °C, products were separated by electrophoresis through non-denaturing 4-12% polyacrylamide gels in 0.5x TBE (45 mM Tris, 45 mM boric acid, and 1 mM EDTA, pH 8.3) at 120 V for 2 h at 20 °C. Results were detected using a Molecular Imager FX and Quantity One software (Bio-Rad). Antibody supershift and competition experiments were performed as described previously (19). The top strand of competitor oligonucleotides is as follows: Spi 2.1 Stat5 binding sites, 5'-ACGCTTCTACTAATCCATGTTCTGAGAAATCATCCAGTCTGCCCA-3', and Oct-1, 5'-TTTTAGAGGATCCATGCAAATGGACGTACG-3'.

RNA Analysis—Hepatic nuclear RNA was isolated as described previously (12). RNA concentration was determined spectrophotometrically at 260 nm, and its quality was assessed by agarose gel electrophoresis. Nuclear RNA (5 µg) was reverse-transcribed with random hexamers in a final volume of 20 µl using a RT-PCR kit (Invitrogen). PCR reactions were then performed with 0.5 µl of cDNA (15). Primer sequences are listed in Table I. The linear range of product amplification was established in pilot studies for each primer pair, and the cycle number that reflected the approximate midpoint was used in final experiments. This varied from 20 to 28 cycles. Results were quantified by densitometry after electrophoresis through 1.5% agarose gels.


View this table:
[in this window]
[in a new window]
  		TABLE I
Primers used for RT-PCR of nuclear RNA

 
Chromatin Immunoprecipitation Assays (ChIP)—Initial steps were modified from published protocols (20). For each time point, a 200-mg fragment of rat liver was minced and incubated at 20 °C in 10 ml of Dulbecco's modified Eagle's medium plus 1% formaldehyde on a rotating platform for 15 min followed by the addition of 1.5 ml of 1 M glycine and incubation for an additional 5 min. After centrifugation at 200 x g for 5 min at 20 °C, the pellet was suspended in 1 ml of phosphate-buffered saline, transferred to a 2-ml Dounce apparatus, and homogenized with 10 strokes of a tight fitting pestle. After brief centrifugation in a microcentrifuge, the pellet was suspended in 400 µl of lysis buffer (50 mM Tris-HCl, 5 mM EDTA, 1% SDS, pH 8.1, plus protease inhibitors) and incubated for 15 min at 4 °C. Each sample was sonicated at 4 °C using a total of 5 pulses for 15 s each of a Branson Micro-tip sonicator at setting 5 interspersed with 30-s incubations on ice. After centrifugation at 14,000 x g for 10 min at 4 °C in a microcentrifuge, the supernatant was diluted 10-fold with immunoprecipitation buffer (20 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, pH 8.1, plus protease inhibitors) and 1-ml aliquots were used for immunoprecipitation as described previously (20) with 3 µl of the Stat5 C17X antibody and 45 µl of a 50% slurry of protein A-agarose beads. DNA was extracted from the immunoprecipitates using the Qiaquick PCR DNA purification kit and a protocol from the supplier and was suspended in 50 µl of 10 mM Tris-HCl, 1 mM EDTA, pH 8.0. PCR reactions were performed with 1 µl of DNA using the primer pairs listed in Table II. The linear range of product amplification was established for each primer pair in pilot studies, and the cycle number that reflected the approximate midpoint was used in final experiments. This varied from 28 to 30 cycles. Results were visualized after electrophoresis through 1.5% agarose gels.


View this table:
[in this window]
[in a new window]
  		TABLE II
Primers used for PCR in ChIP assays

 

   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Identification of a GH-regulated Stat5 Binding Site within the Rat IGF-I Gene—In past studies, we mapped a GH-stimulated DNase I-hypersensitive site termed HS7 to the second intron of the rat IGF-I gene and demonstrated that alterations in this chromosomal region coincided with GH-stimulated induction of IGF-I gene transcription in vivo (12). More recently, we found that Stat5b was required for acute activation of IGF-I gene transcription by GH (15). The latter observations prompted the analysis of the IGF-I gene including HS7 for potential Stat5 binding sequences. A map of the first three exons of the rat IGF-I gene is illustrated in Fig. 1A and includes tandem promoters P1 and P2, their leader exons 1 and 2, respectively, and exon 3, which encodes the NH2-terminal half of the mature IGF-I peptide (14). HS7 is located approximately midway between exons 2 and 3 as indicated. The DNA sequence illustrated below the map represents part of the 3' end of HS7. It contains two putative Stat5 binding sites labeled GHRE-1 and GHRE-2, respectively, which both conform to the consensus of 5'-TTCNNNGAA-3' (21). Fig. 1B demonstrates that this 84-bp region of the rat IGF-I gene is fairly well conserved in two other mammalian species and that GHRE-1 is preserved as a potential Stat binding site among rat, mouse, and human IGF-I genes. There is additionally an ~85% identity over the 900 bp flanking the 84-bp HS7 core DNA sequence between rats and mice and an ~64% identity between rat and human IGF-I genes (data not shown).



View larger version (38K):
[in this window]
[in a new window]
  		FIG. 1.
Diagram of the rat IGF-I gene showing the location of HS7, the region containing two putative GH response elements. A, map of the 5' half of the 6-exon rat IGF-I gene. Exons are indicated by boxes with coding regions in black and non-coding segments in gray. The two promoters, P1 and P2, are shown as well as the location between exons 2 and 3 of DNase I-HS7, found previously to be altered in chromatin in rat hepatic nuclei after acute GH treatment (12). Also illustrated are approximate locations of oligonucleotide primers used for ChIP (black) or RT-PCR experiments (light gray). A 1-kb scale bar is shown. The DNA sequence below the map lists the 84-bp segment containing two potential GH response elements, GHRE-1 and GHRE-2 (underlined). B, comparative anatomy of the chromosomal region spanning GHRE-1 and GHRE-2 in human, rat, and mouse IGF-I genes. Identical nucleotides between two species are shaded in gray and among all three species are shaded in black. GHRE-1 and GHRE-2 are boxed.

 
Chromatin immunoprecipitation experiments were performed to determine whether the IGF-I HS7 region was capable of binding Stat5 in vivo in a GH-dependent way. As shown in Fig. 2A, in liver chromatin from GH-deficient rats, little Stat5 could be detected in association with HS7. Within 15 min of systemic hormone injection, Stat5 was found in chromatin at the HS7 site and this protein-DNA interaction persisted for the 60-min duration of the experiments. Nearly identical binding kinetics were observed at the proximal promoter of the GH-activated Sp12.1 gene, which contains tandem Stat5 sites (22), although no binding of Stat5 was observed at IGF-I intron 3 or proximal promoter 1 or to portions of the c-fos or {beta}-actin genes, indicating that Stat5 was not being non-specifically cross-linked to DNA in liver chromatin.



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 2.
GH stimulates binding of Stat5 to the HS7 region of the rat IGF-I gene prior to activating IGF-I gene transcription. A, results of ChIP assays using an antibody to Stat5 and livers from pituitary-deficient male rats injected with recombinant rat GH for the times indicated. The locations of oligonucleotide primers used for the IGF-I gene are indicated in Fig. 1. Sequences for all of the primers may be found in Table II. B, time course of accumulation of nascent nuclear transcripts for IGF-I, Spi 2.1, c-fos, and {beta}-actin genes after GH treatment as measured by semi-quantitative RT-PCR. No transcripts were observed in the absence of the reverse transcription step, indicating no contamination with chromosomal DNA. Results for both A and B are representative of three independent experiments.

 
Hormone-dependent gene transcription was next assessed to evaluate the functional consequences of GH-stimulated Stat5 binding to the HS7 region of the rat IGF-I gene. Hepatic nuclear RNA was isolated from the same livers used for ChIP assays, and the accumulation of nascent transcripts was measured by semi-quantitative RT-PCR. As seen in Fig. 2B, transcripts directed by IGF-I promoters 1 and 2 were both strongly induced within 30 min after systemic GH injection and were increased in abundance by 60 min. Similar results were observed for Spi 2.1 gene activation. In this experimental model, GH also transiently induced c-fos gene expression as shown previously (23) but had little effect on {beta}-actin. Thus, in vivo GH treatment rapidly and potently stimulates binding of Stat5 to the HS7 site in the second intron of the rat IGF-I gene in the liver followed by activation of transcription from both IGF-I promoters.

DNA Binding Properties of GHRE-1 and GHRE-2—We used gel-mobility shift experiments to determine whether Stat5b could bind directly to GHRE-1 or GHRE-2. Fig. 3A shows results using labeled double-stranded oligonucleotides for each element. Nuclear protein extracts were prepared from COS-7 cells transfected with expression plasmids for the mouse GH receptor and either wild type or constitutively active rat Stat5b and treated with GH or vehicle for 30 min. As seen in Fig. 3A, GH induced the binding of wild type Stat5b to both DNA probes, whereas constitutively active Stat5b was able to bind in the absence of hormone. Antibody supershift experiments confirmed that Stat5b interacted with each oligonucleotide.



View larger version (44K):
[in this window]
[in a new window]
  		FIG. 3.
Assessing binding of Stat 5b to GHRE-1 and GHRE-2. A, results of gel-mobility shift assays using double-stranded oligonucleotides for either GHRE-1 or GHRE-2 and nuclear protein extracts from COS-7 cells transfected with expression plasmids encoding the mouse GH receptor and either wild type (WT) or constitutively active NH2-terminal FLAG-tagged rat Stat5b and incubated with rat GH (40 nM) or vehicle for 30 min. In cells transfected with wild type Stat5b, a protein-DNA complex is seen only after GH treatment (lane 2 versus lane 1 and lane 6 versus lane 5, arrow), whereas in cells expressing constitutively active Stat5b, a complex is observed in the absence of hormone (lanes 3 and 7, arrow). Lanes 4 and 8 demonstrate that an antibody to the FLAG epitope causes a supershift of each DNA-protein complex (upper arrow). A thin arrow denotes the location of free probe (FP). B, inducible binding after in vivo GH treatment of rat hepatic nuclear protein extracts to a double-stranded oligonucleotide for GHRE-1 as assessed by gel-mobility shift experiment (lanes 1-4). Lanes 5-8 show that binding of the same nuclear protein extracts to a double-stranded oligonucleotide for Sp-1 is relatively constant after GH. The locations of FP and each gel shift are indicated by arrows. C, specific binding of rat hepatic nuclear protein extracts (GH, 60 min) to GHRE-1. Results are shown of gel-mobility shift experiments using double-stranded competitor oligonucleotides for GHRE-1, GHRE-2, the Spi 2.1 Stat5 binding site (Spi 2.1), and the recognition sequence for the transcription factor Oct-1. All of the DNA sequences are listed under "Experimental Procedures." Only oligonucleotides for GHRE-1 and Spi 2.1 compete with the labeled GHRE-1 probe. The locations of FP and the specific gel shift are indicated. All of the experiments in A-C have been performed three times with comparable results.

 
We next evaluated the binding of endogenous hepatic Stat5 to the putative GHREs in HS7. Shown in Fig. 3B are results using labeled GHRE-1 and nuclear protein extracts from GH-deficient rats acutely treated with hormone. Inducible binding was observed beginning within 15 min after systemic GH injection and reached a maximum by 30-60 min. Under the conditions used in these experiments, no binding to a GHRE-2 oligonucleotide could be detected (data not shown), implying that it is a lower affinity site compared with GHRE-1. As a control, gel-mobility shift assays were performed with a double-stranded oligonucleotide that recognizes members of the Sp1 family of transcription factors (24) that are not regulated by GH. As expected, constant protein-DNA interactions were observed over the same time course, indicating that both the quantity and quality of nuclear protein extracts were similar at each time point after hormone treatment.

The relative affinity of GHRE-1 for hepatic Stat5 was assessed using liver nuclear proteins isolated at 60 min after injection of GH and a variety of unlabeled competitor oligonucleotides. As shown in Fig. 3C, GHRE-1 competed avidly with itself for nuclear protein binding, whereas GHRE-2 competed poorly, even at a x100 molar concentration. The contiguous Stat5 binding sites from the Spi 2.1 gene promoter competed with GHRE-1 but only at x100 concentration, and the unrelated binding site for the Oct-1 transcription factor (24) was ineffective. Taken together, the results in Fig. 3 show that GHRE-1 and GHRE-2 are bona fide Stat5 binding elements and that the affinity of Stat5 for GHRE-1 is greater than that for GHRE-2.

GHRE-1 and GHRE-2 Mediate GH-activated and Stat5b-dependent Gene Transcription—We used reconstitution experiments in COS-7 cells to evaluate the transcriptional properties of HS7 and GHRE-1 and GHRE-2. Cells were transiently transfected with expression plasmids for the mouse GH receptor and rat Stat5b and luciferase fusion genes containing rat IGF-I promoter 1 alone or with an 825-bp fragment of rat HS7 including GHRE-1 and GHRE-2. As shown in Fig. 4, GH treatment had no effect on the activity of the native IGF-I promoter but induced a 3.5-fold increase in luciferase activity of fusion genes containing the HS7 segment.

To extend this observation of GH-stimulated gene transcription through HS7, additional reconstitution experiments were performed with luciferase reporter genes containing a minimal thymidine kinase promoter. As pictured in Fig. 5A, in the presence of GHRE-1 and GHRE-2 and Stat5b, GH induced a 6-7-fold increase in luciferase activity. The importance of the two GHREs for hormonal regulation was next evaluated after engineering point mutations into each site. As illustrated in Fig. 5B, a ~8-fold increase in luciferase was detected after GH when both GHREs were present. The hormonal response dropped to ~4-fold when only one GHRE was intact and declined to <1.4-fold when both were mutated. In addition, four copies of GHRE-1 were able to transfer an ~7-fold response to GH onto the minimal thymidine kinase promoter (data not shown). Thus, each GHRE is capable of mediating GH-induced gene transcription in the presence of Stat5b.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
A long-standing challenge in the field of growth biology has been to understand the biochemical mechanisms by which GH activates IGF-I gene expression. Here we identify binding sites for the transcription factor Stat5 in a region within the second intron of the rat IGF-I gene previously shown to undergo a GH-stimulated chromatin transition coincident with hormone-induced IGF-I transcription (12). We show that this segment of the IGF-I gene binds Stat5 in vivo in a GH-dependent way just prior to the onset of IGF-I gene activation, can bind Stat5b in vitro, and is sufficient to mediate hormone-regulated and Stat5b-dependent reporter gene expression in the context of both the major IGF-I gene promoter and a minimal thymidine kinase promoter. Taken together, these results show that Stat5b is a key protein responsible for the induction of IGF-I gene transcription by GH and define the molecular architecture of this transcriptional response.

Previous gene knock-out studies have established a role for Stat5b and to a lesser extent Stat5a in the physiological pathways responsible for normal somatic growth in rodents (16, 17). In the absence of these proteins, mice developed up to a 30% deficit in postnatal linear growth that was associated with an ~50% decline in serum levels of IGF-I (16, 17). More recently, we found that forced expression of a dominant-negative version of Stat5b in GH-deficient rats blocked the acute activation of IGF-I transcription by GH, whereas constitutively active Stat5b stimulated IGF-I gene expression in the absence of hormone (15). Both groups of observations implicated Stat5b in IGF-I gene regulation but did not identify specific biochemical mechanisms, a question that we now have addressed.

Members of the Stat family of transcription factors bind as dimers to DNA response elements consisting of variants of the palindromic nucleotide sequence 5'-TTCN2-4GAA-3' where N signifies any deoxyribonucleotide (21). Ehret et al. (25) recently showed that Stats 1 and 5 preferentially bind to sites where n = 3 (25). This is the precise spacing of IGF-I GHRE-1 and GHRE-2. Based on their results, we find additionally that GHRE-1 is identical in its core DNA sequence to Stat5 binding sites in the Cis and T cell receptor {gamma} genes and that GHRE-2 is identical to the Stat5 response element in the {alpha}s1 casein gene (25), thus providing further evidence supporting our experimental data that GHRE-1 and GHRE-2 are bona fide Stat5 binding sequences.

The exact biochemical steps by which Stat5 activates target gene transcription remain incompletely understood. Previous studies established that the COOH-terminal transcription activation region of the protein could interact directly with the transcriptional co-activators CREB-binding protein and p300 (26, 27), a process that led to chromatin modifications including histone acetylation (26, 27), and that transcription was facilitated by another Stat5-interacting protein, Nmi (28). Others have identified the widely expressed protein, centrosomal P4.1-associated protein, as a second co-activator of Stat5 that also physically interacted with the COOH terminus of the protein (29).

More recent studies have focused on the surprising observation that upon binding of activated Stat5 to regulatory sites on target genes, an associated histone deacetylase activity was enhanced (30, 31). In one series of experiments, the deacetylase inhibitor trichostatin A globally blocked cytokine-induced activation of Stat5-dependent genes (30). In another study, recruitment of the histone deacetylase, HDAC-1, to the Id-1 promoter by active Stat5 led to deacetylation of the transcription factor CCAAT/enhancer-binding protein {beta}, events that were required for induction of Id-1 transcription (31). Our observations do not shed light on whether co-regulatory proteins with either acetyltransferase or deacetylase activity associate with Stat5 on the IGF-I gene but do provide a robust model system for answering this question.

GH and IGF-I play central roles in human physiology. They are essential for normal growth during fetal and postnatal development and are critical for tissue maintenance and repair during aging (2-5, 7, 8). In contrast, normal levels of both proteins have been found to have potential pathogenic consequences, being linked by epidemiological studies to several cancers (32). Thus, a full understanding of the molecular mechanisms by which GH regulates IGF-I gene expression will be necessary for developing effective therapeutic strategies to use these potent agents safely (33).


   FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Supported by a research fellowship from the European Society for Pediatric Endocrinology sponsored by Novo Nordisk and the Eli Lilly International Foundation. Back

|| Supported by a research fellowship from the Lawson Wilkins Pediatric Endocrinology Society sponsored by Eli Lilly. Back

** To whom correspondence should be addressed: Oregon Health & Science University, Molecular Medicine Division, 3181 S. W. Sam Jackson Park Rd., Mail code HRC3, Portland, OR 97239-3098. Tel.: 503-494-0536; Fax: 503-494-7368; E-mail: rotweinp{at}ohsu.edu.

1 The abbreviations used are: GH, growth hormone; IGF, insulin-like growth factor; Stat, signal transducers and activators of transcription; RT, reverse transcription; ChIP, chromatin immunoprecipitation assays; HS7, hypersensitive site 7; GHRE, GH response element. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Mylynda Schlesinger-Massart for comments on the paper and Drs. Susan Berry, Christin Carter-Su, and Frank Talamantes for gifts of recombinant plasmids.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Salmon, W. D., and Daughaday, W. H. (1957) J. Lab. Clin. Med. 49, 825-836[Medline] [Order article via Infotrieve]
  2. Herrington, J., and Carter-Su, C. (2001) Trends Endocrinol. Metab. 12, 252-257[CrossRef][Medline] [Order article via Infotrieve]
  3. Jones, J. I., and Clemmons, D. R. (1995) Endocr. Rev. 16, 3-34[Abstract/Free Full Text]
  4. Lupu, F., Terwilliger, J. D., Lee, K., Segre, G. V., and Efstratiadis, A. (2001) Dev. Biol. 229, 141-162[CrossRef][Medline] [Order article via Infotrieve]
  5. Daughaday, W. H., and Rotwein, P. (1989) Endocr. Rev. 10, 68-91[Abstract/Free Full Text]
  6. Adamo, M. L. (1995) Diabetes Rev. 3, 2-27
  7. Schoenle, E., Zapf, J., Humbel, R. E., and Froesch, E. R. (1982) Nature 296, 252-253[CrossRef][Medline] [Order article via Infotrieve]
  8. Guler, H. P., Zapf, J., Scheiwiller, E., and Froesch, E. R. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 4889-4893[Abstract/Free Full Text]
  9. Le Roith, D., Bondy, C., Yakar, S., Liu, J. L., and Butler, A. (2001) Endocr. Rev. 22, 53-74[Abstract/Free Full Text]
  10. Yakar, S., Rosen, C. J., Beamer, W. G., Ackert-Bicknell, C. L., Wu, Y., Liu, J. L., Ooi, G. T., Setser, J., Frystyk, J., Boisclair, Y. R., and LeRoith, D. (2002) J. Clin. Invest. 110, 771-781[CrossRef][Medline] [Order article via Infotrieve]
  11. Rotwein, P., Thomas, M. J., Harris, D. M., Gronowski, A. M., and LeStunff, C. (1997) J. Anim. Sci. 75, 11-19[Abstract/Free Full Text]
  12. Bichell, D. P., Kikuchi, K., and Rotwein, P. (1992) Mol. Endocrinol. 6, 1899-1908[Abstract/Free Full Text]
  13. D'Ercole, A. J., Stiles, A. D., and Underwood, L. E. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 935-939[Abstract/Free Full Text]
  14. Rotwein, P. (1999) in Contemporary Endocrinology: The IGF System (Rosenfeld, R., and Roberts, C. J., eds) pp. 19-35, Humana Press, Totowa, NJ
  15. Woelfle, J., Billiard, J., and Rotwein, P. (2003) J. Biol. Chem. 278, 22696-22702[Abstract/Free Full Text]
  16. Udy, G. B., Towers, R. P., Snell, R. G., Wilkins, R. J., Park, S. H., Ram, P. A., Waxman, D. J., and Davey, H. W. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7239-7244[Abstract/Free Full Text]
  17. Teglund, S., McKay, C., Schuetz, E., van Deursen, J. M., Stravopodis, D., Wang, D., Brown, M., Bodner, S., Grosveld, G., and Ihle, J. N. (1998) Cell 93, 841-850[CrossRef][Medline] [Order article via Infotrieve]
  18. Thomas, M. J., Umayahara, Y., Shu, H., Centrella, M., Rotwein, P., and McCarthy, T. L. (1996) J. Biol. Chem. 271, 21835-21841[Abstract/Free Full Text]
  19. Gronowski, A. M., and Rotwein, P. (1994) J. Biol. Chem. 269, 7874-7878[Abstract/Free Full Text]
  20. Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., and Brown, M. (2000) Cell 103, 843-852[CrossRef][Medline] [Order article via Infotrieve]
  21. Horvath, C. M. (2000) Trends Biochem. Sci. 25, 496-502[CrossRef][Medline] [Order article via Infotrieve]
  22. Berry, S. A., Bergad, P. L., Whaley, C. D., and Towle, H. C. (1994) Mol. Endocrinol. 8, 1714-1719[Abstract/Free Full Text]
  23. Gronowski, A. M., and Rotwein, P. (1995) Endocrinology 136, 4741-4748[Abstract]
  24. Boulikas, T. (1994) Crit. Rev. Eukaryot. Gene Expr. 4, 117-321[Medline] [Order article via Infotrieve]
  25. Ehret, G. B., Reichenbach, P., Schindler, U., Horvath, C. M., Fritz, S., Nabholz, M., and Bucher, P. (2001) J. Biol. Chem. 276, 6675-6688[Abstract/Free Full Text]
  26. Pfitzner, E., Jahne, R., Wissler, M., Stoecklin, E., and Groner, B. (1998) Mol. Endocrinol. 12, 1582-1593[Abstract/Free Full Text]
  27. Ye, S. K., Agata, Y., Lee, H. C., Kurooka, H., Kitamura, T., Shimizu, A., Honjo, T., and Ikuta, K. (2001) Immunity 15, 813-823[CrossRef][Medline] [Order article via Infotrieve]
  28. Zhu, M., John, S., Berg, M., and Leonard, W. J. (1999) Cell 96, 121-130[CrossRef][Medline] [Order article via Infotrieve]
  29. Peng, B., Sutherland, K. D., Sum, E. Y., Olayioye, M., Wittlin, S., Tang, T. K., Lindeman, G. J., and Visvader, J. E. (2002) Mol. Endocrinol. 16, 2019-2033[Abstract/Free Full Text]
  30. Rascle, A., Johnston, J. A., and Amati, B. (2003) Mol. Cell. Biol. 23, 4162-4173[Abstract/Free Full Text]
  31. Xu, M., Nie, L., Kim, S. H., and Sun, X. H. (2003) EMBO J. 22, 893-904[CrossRef][Medline] [Order article via Infotrieve]
  32. Pollak, M. (2000) Growth Horm. IGF Res. 10, 521-524
  33. Kaspar, B. K. Llado, J. Sherkat, N. Rothstein, J. D., and Gage, F. H. (2003) Science 301, 839-842[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
N. Moller, L. C. Gormsen, O. Schmitz, S. Lund, J. O. L. Jorgensen, and N. Jessen
Free Fatty Acids Inhibit Growth Hormone/Signal Transducer and Activator of Transcription-5 Signaling in Human Muscle: A Potential Feedback Mechanism
J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2204 - 2207.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
X. Wang, N. Yang, L. Deng, X. Li, J. Jiang, Y. Gan, and S. J. Frank
Interruption of Growth Hormone Signaling via SHC and ERK in 3T3-F442A Preadipocytes upon Knockdown of Insulin Receptor Substrate-1
Mol. Endocrinol., April 1, 2009; 23(4): 486 - 496.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
N. Moller and J. O. L. Jorgensen
Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects
Endocr. Rev., April 1, 2009; 30(2): 152 - 177.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
W. Matheny, E. Merritt, S. V. Zannikos, R. P. Farrar, and M. L. Adamo
Serum IGF-I-Deficiency Does Not Prevent Compensatory Skeletal Muscle Hypertrophy in Resistance Exercise
Experimental Biology and Medicine, February 1, 2009; 234(2): 164 - 170.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. D. Buzzelli, M. Nagarajan, J. F. Radtka, M. L. Shumate, M. Navaratnarajah, C. H. Lang, and R. N. Cooney
Nuclear Factor-{kappa}B Mediates the Inhibitory Effects of Tumor Necrosis Factor-{alpha} on Growth Hormone-Inducible Gene Expression in Liver
Endocrinology, December 1, 2008; 149(12): 6378 - 6388.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
X. Hong, H.-J. Tsai, X. Liu, Z. Li, X. Liu, G. Tang, H. Xing, J. Yang, B. Wang, Y. Feng, et al.
A Large-Scale Genome-Wide Linkage Analysis to Map Loci Linked to Stature in Chinese Population
J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4511 - 4518.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B.-M. Zhu, S. K. McLaughlin, R. Na, J. Liu, Y. Cui, C. Martin, A. Kimura, G. W. Robinson, N. C. Andrews, and L. Hennighausen
Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression
Blood, September 1, 2008; 112(5): 2071 - 2080.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Nielsen, L. C. Gormsen, N. Jessen, S. B. Pedersen, N. Moller, S. Lund, and J. O. L. Jorgensen
Growth Hormone Signaling in Vivo in Human Muscle and Adipose Tissue: Impact of Insulin, Substrate Background, and Growth Hormone Receptor Blockade
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2842 - 2850.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Eleswarapu, Z. Gu, and H. Jiang
Growth Hormone Regulation of Insulin-Like Growth Factor-I Gene Expression May Be Mediated by Multiple Distal Signal Transducer and Activator of Transcription 5 Binding Sites
Endocrinology, May 1, 2008; 149(5): 2230 - 2240.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Jiang, Y. Wang, M. Wu, Z. Gu, S. J. Frank, and R. Torres-Diaz
Growth Hormone Stimulates Hepatic Expression of Bovine Growth Hormone Receptor Messenger Ribonucleic Acid through Signal Transducer and Activator of Transcription 5 Activation of a Major Growth Hormone Receptor Gene Promoter
Endocrinology, July 1, 2007; 148(7): 3307 - 3315.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Ono, D. J. Chia, R. Merino-Martinez, A. Flores-Morales, T. G. Unterman, and P. Rotwein
Signal Transducer and Activator of Transcription (Stat) 5b-Mediated Inhibition of Insulin-Like Growth Factor Binding Protein-1 Gene Transcription: A Mechanism for Repression of Gene Expression by Growth Hormone
Mol. Endocrinol., June 1, 2007; 21(6): 1443 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Thangavel and B. H. Shapiro
A Molecular Basis for the Sexually Dimorphic Response to Growth Hormone
Endocrinology, June 1, 2007; 148(6): 2894 - 2903.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
T. A. Ahmed, M. D. Buzzelli, C. H. Lang, J. B. Capen, M. L. Shumate, M. Navaratnarajah, M. Nagarajan, and R. N. Cooney
Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes
Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1793 - G1803.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K.-C. Leung, J. Brce, N. Doyle, H. J. Lee, G. M. Leong, K. Sjogren, and K. K. Y. Ho
Regulation of Growth Hormone Signaling by Selective Estrogen Receptor Modulators Occurs through Suppression of Protein Tyrosine Phosphatases
Endocrinology, May 1, 2007; 148(5): 2417 - 2423.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. J. Frank
Growth Hormone, Insulin-Like Growth Factor I, and Growth: Local Knowledge
Endocrinology, April 1, 2007; 148(4): 1486 - 1488.
[Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
O. M. Vidal, R. Merino, E. Rico-Bautista, L. Fernandez-Perez, D. J. Chia, J. Woelfle, M. Ono, B. Lenhard, G. Norstedt, P. Rotwein, et al.
In Vivo Transcript Profiling and Phylogenetic Analysis Identifies Suppressor of Cytokine Signaling 2 as a Direct Signal Transducer and Activator of Transcription 5b Target in Liver
Mol. Endocrinol., January 1, 2007; 21(1): 293 - 311.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Han, B. Osuntokun, N. Benight, K. Loesch, S. J. Frank, and L. A. Denson
Signal Transducer and Activator of Transcription 5b Promotes Mucosal Tolerance in Pediatric Crohn's Disease and Murine Colitis
Am. J. Pathol., December 1, 2006; 169(6): 1999 - 2013.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
S. J. Frank, X. Wang, K. He, N. Yang, P. Fang, R. G. Rosenfeld, V. Hwa, T. R. Chaudhuri, L. Deng, and K. R. Zinn
In Vivo Imaging of Hepatic Growth Hormone Signaling
Mol. Endocrinol., November 1, 2006; 20(11): 2819 - 2830.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. M. Wilson and P. Rotwein
Control of MyoD Function during Initiation of Muscle Differentiation by an Autocrine Signaling Pathway Activated by Insulin-like Growth Factor-II
J. Biol. Chem., October 6, 2006; 281(40): 29962 - 29971.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
T. Ahmed, G. Yumet, M. Shumate, C. H. Lang, P. Rotwein, and R. N. Cooney
Tumor necrosis factor inhibits growth hormone-mediated gene expression in hepatocytes
Am J Physiol Gastrointest Liver Physiol, July 1, 2006; 291(1): G35 - G44.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
J. W Kim, R. P Rhoads, N. Segoale, N. B Kristensen, D. E Bauman, and Y. R Boisclair
Isolation of the cDNA encoding the acid labile subunit (ALS) of the 150 kDa IGF-binding protein complex in cattle and ALS regulation during the transition from pregnancy to lactation.
J. Endocrinol., June 1, 2006; 189(3): 583 - 593.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
K. H. Clodfelter, M. G. Holloway, P. Hodor, S.-H. Park, W. J. Ray, and D. J. Waxman
Sex-Dependent Liver Gene Expression Is Extensive and Largely Dependent upon Signal Transducer and Activator of Transcription 5b (STAT5b): STAT5b-Dependent Activation of Male Genes and Repression of Female Genes Revealed by Microarray Analysis
Mol. Endocrinol., June 1, 2006; 20(6): 1333 - 1351.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Sotiropoulos, M. Ohanna, C. Kedzia, R. K. Menon, J. J. Kopchick, P. A. Kelly, and M. Pende
Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation
PNAS, May 9, 2006; 103(19): 7315 - 7320.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. J. Chia, E. Subbian, T. M. Buck, V. Hwa, R. G. Rosenfeld, W. R. Skach, U. Shinde, and P. Rotwein
Aberrant Folding of a Mutant Stat5b Causes Growth Hormone Insensitivity and Proteasomal Dysfunction
J. Biol. Chem., March 10, 2006; 281(10): 6552 - 6558.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. S. Huo, R. C. McEachin, T. X. Cui, N. K. Duggal, T. Hai, D. J. States, and J. Schwartz
Profiles of Growth Hormone (GH)-regulated Genes Reveal Time-dependent Responses and Identify a Mechanism for Regulation of Activating Transcription Factor 3 By GH
J. Biol. Chem., February 17, 2006; 281(7): 4132 - 4141.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. J. Chia, M. Ono, J. Woelfle, M. Schlesinger-Massart, H. Jiang, and P. Rotwein
Characterization of Distinct Stat5b Binding Sites That Mediate Growth Hormone-stimulated IGF-I Gene Transcription
J. Biol. Chem., February 10, 2006; 281(6): 3190 - 3197.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
M J Waters, H N Hoang, D P Fairlie, R A Pelekanos, and R J Brown
New insights into growth hormone action
J. Mol. Endocrinol., February 1, 2006; 36(1): 1 - 7.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
K Iida, C J Rosen, C Ackert-Bicknell, and M O Thorner
Genetic differences in the IGF-I gene among inbred strains of mice with different serum IGF-I levels
J. Endocrinol., September 1, 2005; 186(3): 481 - 489.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. A. Kazi, J. M. Jones, and R. D. Koos
Chromatin Immunoprecipitation Analysis of Gene Expression in the Rat Uterus in Vivo: Estrogen-Induced Recruitment of Both Estrogen Receptor {alpha} and Hypoxia-Inducible Factor 1 to the Vascular Endothelial Growth Factor Promoter
Mol. Endocrinol., August 1, 2005; 19(8): 2006 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. L. Shumate, G. Yumet, T. A. Ahmed, and R. N. Cooney
Interleukin-1 inhibits the induction of insulin-like growth factor-I by growth hormone in CWSV-1 hepatocytes
Am J Physiol Gastrointest Liver Physiol, August 1, 2005; 289(2): G227 - G239.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
H. Kim, E. Barton, N. Muja, S. Yakar, P. Pennisi, and D. LeRoith
Intact Insulin and Insulin-Like Growth Factor-I Receptor Signaling Is Required for Growth Hormone Effects on Skeletal Muscle Growth and Function in Vivo
Endocrinology, April 1, 2005; 146(4): 1772 - 1779.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Wang and H. Jiang
Identification of a Distal STAT5-binding DNA Region That May Mediate Growth Hormone Regulation of Insulin-like Growth Factor-I Gene Expression
J. Biol. Chem., March 25, 2005; 280(12): 10955 - 10963.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. E. Rowland, A. M. Lichanska, L. M. Kerr, M. White, E. M. d'Aniello, S. L. Maher, R. Brown, R. D. Teasdale, P. G. Noakes, and M. J. Waters
In Vivo Analysis of Growth Hormone Receptor Signaling Domains and Their Associated Transcripts
Mol. Cell. Biol., January 1, 2005; 25(1): 66 - 77.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
P. Kotokorpi, C. Gardmo, C. S. Nystrom, and A. Mode
Activation of the Glucocorticoid Receptor or Liver X Receptors Interferes with Growth Hormone-Induced akr1b7 Gene Expression in Rat Hepatocytes
Endocrinology, December 1, 2004; 145(12): 5704 - 5713.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Garzon, S. F. Soriano, J. M. Rodriguez-Frade, L. Gomez, A. Martin de Ana, M. Sanchez-Gomez, C. Martinez-A, and M. Mellado
CXCR4-mediated Suppressor of Cytokine Signaling Up-regulation Inactivates Growth Hormone Function
J. Biol. Chem., October 22, 2004; 279(43): 44460 - 44466.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
D. F. Sun, Z. Zheng, P. Tummala, J. Oh, F. Schaefer, and R. Rabkin
Chronic Uremia Attenuates Growth Hormone-Induced Signal Transduction in Skeletal Muscle
J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2630 - 2636.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
F. Tronche, C. Opherk, R. Moriggl, C. Kellendonk, A. Reimann, L. Schwake, H. M. Reichardt, K. Stangl, D. Gau, A. Hoeflich, et al.
Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth
Genes & Dev., March 1, 2004; 18(5): 492 - 497.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/51/51261    most recent
M309486200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Woelfle, J.
Right arrow Articles by Rotwein, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Woelfle, J.
Right arrow Articles by Rotwein, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement